Mirae Asset Global Investments Co., Ltd. Phathom Pharmaceuticals, Inc. Transaction History
Mirae Asset Global Investments Co., Ltd.
- $34.4 Billion
- Q4 2025
A detailed history of Mirae Asset Global Investments Co., Ltd. transactions in Phathom Pharmaceuticals, Inc. stock. As of the latest transaction made, Mirae Asset Global Investments Co., Ltd. holds 3,457 shares of PHAT stock, worth $50,783. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,457
Previous 2,743
26.03%
Holding current value
$50,783
Previous $31,000
61.29%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding PHAT
# of Institutions
154Shares Held
65.5MCall Options Held
1.15MPut Options Held
170K-
Frazier Life Sciences Management, L.P. Menlo Park, CA12.5MShares$183 Million6.03% of portfolio
-
Medicxi Ventures Management (Jersey) LTD7.46MShares$110 Million14.46% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.08MShares$74.6 Million0.03% of portfolio
-
Invesco Ltd. Atlanta, GA3.86MShares$56.8 Million0.01% of portfolio
-
Carlyle Group Inc. Washington, DC3.5MShares$51.4 Million50.16% of portfolio
About Phathom Pharmaceuticals, Inc.
- Ticker PHAT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 39,175,200
- Market Cap $575M
- Description
- Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also develo...